Author:
Boot Erik,Butcher Nancy J.,Udow Sean,Marras Connie,Mok Kin Y.,Kaneko Satoshi,Barrett Matthew J.,Prontera Paolo,Berman Brian D.,Masellis Mario,Dufournet Boris,Nguyen Karine,Charles Perrine,Mutez Eugénie,Danaila Teodor,Jacquette Aurélia,Colin Olivier,Drapier Sophie,Borg Michel,Fiksinski Ania M.,Vergaelen Elfi,Swillen Ann,Vogels Annick,Plate Annika,Perandones Claudia,Gasser Thomas,Clerinx Kristien,Bourdain Frédéric,Mills Kelly,Williams Nigel M.,Wood Nicholas W.,Booij Jan,Lang Anthony E.,Bassett Anne S.,
Abstract
ObjectiveTo delineate the natural history, diagnosis, and treatment response of Parkinson disease (PD) in individuals with 22q11.2 deletion syndrome (22q11.2DS), and to determine if these patients differ from those with idiopathic PD.MethodsIn this international observational study, we characterized the clinical and neuroimaging features of 45 individuals with 22q11.2DS and PD (mean follow-up 7.5 ± 4.1 years).Results22q11.2DS PD had a typical male excess (32 male, 71.1%), presentation and progression of hallmark motor symptoms, reduced striatal dopamine transporter binding with molecular imaging, and initial positive response to levodopa (93.3%). Mean age at motor symptom onset was relatively young (39.5 ± 8.5 years); 71.4% of cases had early-onset PD (<45 years). Despite having a similar age at onset, the diagnosis of PD was delayed in patients with a history of antipsychotic treatment compared with antipsychotic-naive patients (median 5 vs 1 year, p = 0.001). Preexisting psychotic disorders (24.5%) and mood or anxiety disorders (31.1%) were common, as were early dystonia (19.4%) and a history of seizures (33.3%).ConclusionsMajor clinical characteristics and response to standard treatments appear comparable in 22q11.2DS-associated PD to those in idiopathic PD, although the average age at onset is earlier. Importantly, treatment of preexisting psychotic illness may delay diagnosis of PD in 22q11.DS patients. An index of suspicion and vigilance for complex comorbidity may assist in identifying patients to prioritize for genetic testing.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献